Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Mar 1974|
ASJC Scopus subject areas
- Cancer Research